Conditions: Familial Chylomicronemia Syndrome
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 67
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 52 weeks in participants with Familial Chylomicronemia Syndrome

Detailed description:

Arms:
arm 1: Volanesorsen-matching placebo administered subcutaneously once-weekly for 52 weeks. arm 2: Volanesorsen 300 mg administered subcutaneously once-weekly for 52 weeks.

Interventions: intervention 1: Volanesorsen intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: